Clinical Trials Logo

ER+ Breast Cancer clinical trials

View clinical trials related to ER+ Breast Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05423730 Completed - Breast Cancer Clinical Trials

Alcohol and Breast Cancer (ABC) Trial

Start date: September 1, 2022
Phase: Early Phase 1
Study type: Interventional

This research study is a pilot study, which is the first time investigators are examining the effect of light alcohol consumption on sex hormones among postmenopausal women with estrogen receptor-positive (ER+) breast cancer taking an aromatase inhibitor The names of the study exposures involved in this study are: - White wine - White grape juice

NCT ID: NCT04312347 Completed - ER+ Breast Cancer Clinical Trials

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

Start date: September 6, 2019
Phase: N/A
Study type: Interventional

The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.

NCT ID: NCT02580448 Completed - Breast Cancer Clinical Trials

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

CLARITY-01
Start date: August 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical study is to determine the safety, pharmacokinetics, pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.

NCT ID: NCT01202591 Completed - ER+ Breast Cancer Clinical Trials

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

GLOW
Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)

NCT ID: NCT00828854 Completed - ER+ Breast Cancer Clinical Trials

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Start date: October 1, 2008
Phase: Phase 2
Study type: Interventional

The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor. It is hypothesized that entinostat with continued AI will increase the estimated AI clinical benefit rate (CBR) from 5% to 25% with an acceptable safety profile.

NCT ID: NCT00676663 Completed - Breast Cancer Clinical Trials

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

ENCORE301
Start date: June 13, 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.